...
首页> 外文期刊>Experimental and therapeutic medicine >MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1
【24h】

MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1

机译:MicroRNA-22通过瞄准SIRT1抑制乳腺癌中的细胞生长和转移

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs (miRs), which are a class of small non-coding RNAs, are key regulators of gene expression via induction of translational repression or mRNA degradation. However, the molecular mechanism of miR-22 underlying the malignant progression of breast cancer, remains to be elucidated. The present study aimed to explore the regulatory mechanism of miR-22 in breast cancer cell growth and metastasis. Reverse transcription-quantitative polymerase chain reaction data revealed that miR-22 was significantly downregulated in breast cancer tissues, compared with adjacent non-tumor tissues. Furthermore, the miR-22 levels were further decreased in stage III-IV, compared with stage I-II breast cancer. In addition, low miR-22 levels were significantly associated with the poor differentiation, metastasis and advanced clinical stages of breast cancer. Sirtuin1 (SIRT1) was demonstrated to act as a direct target gene of miR-22 and its protein expression negatively regulated by miR-22 in the MCF-7 breast cancer cell line. Furthermore, SIRT1 expression levels were significantly upregulated in breast cancer tissues, compared with adjacent non-tumor tissues. SIRT1 levels were observed to be increased in stage III-IV when compared with stage I-II breast cancer. miR-22 overexpression decreased the proliferation, migration and invasion of MCF-7 cells, whereas overexpression of SIRT1 eliminated the suppressive effects of the miR-22 overexpression on the malignant phenotype of MCF-7 cells. The results of the present study therefore suggested that miR-22 demonstrated suppressive effects on breast cancer growth and metastasis via targeting SIRT1, and thus the miR-22/SIRT1 axis may be used as a novel and potential therapeutic target for breast cancer in the future.
机译:MicroRNAS(MIRS)是一类小的非编码RNA,是通过诱导平移抑制或mRNA降解的基因表达的关键调节因子。然而,MiR-22潜在乳腺癌恶性进展的分子机制仍有待阐明。本研究旨在探讨miR-22在乳腺癌细胞生长和转移中的调节机制。逆转录定量聚合酶链反应数据显示,与相邻的非肿瘤组织相比,MIR-22在乳腺癌组织中显着下调。此外,与第I-II阶段乳腺癌相比,III-IV阶段进一步降低miR-22水平。此外,低miR-22水平与乳腺癌的差异,转移和晚期临床阶段显着相关。 Sirtuin1(SIRT1)被证明用作MIR-22的直接靶基因及其在MCF-7乳腺癌细胞系中的miR-22负调节的蛋白表达。此外,与相邻的非肿瘤组织相比,乳腺癌组织中SIRT1表达水平显着上调。与第I-II阶段乳腺癌相比,观察到SIRT1水平在阶段III-IV中增加。 miR-22过表达降低了MCF-7细胞的增殖,迁移和侵袭,而SIRT1的过度表达消除了MIR-22过表达对MCF-7细胞恶性表型的抑制作用。因此,本研究的结果表明MIR-22通过靶向SIRT1对乳腺癌生长和转移进行了抑制作用,因此MIR-22 / SIRT1轴可以用作未来乳腺癌的新颖和潜在治疗靶标。

著录项

  • 来源
  • 作者单位

    Jinan Univ Dept Breast Surg Affiliated Hosp 1 Guangzhou 510632 Guangdong Peoples R China;

    Youjiang Med Univ Nationalities Dept Gen Surg Affiliated Hosp 18 Zhongshan Er Rd Baise 533000;

    Peoples Hosp Guangxi Zhuang Autonomous Reg Dept Hepatobiliary &

    Endocrine Surg Nanning 530021;

    Peoples Hosp Guangxi Zhuang Autonomous Reg Dept Hepatobiliary &

    Endocrine Surg Nanning 530021;

    Peoples Hosp Guangxi Zhuang Autonomous Reg Dept Hepatobiliary &

    Endocrine Surg Nanning 530021;

    Peoples Hosp Guangxi Zhuang Autonomous Reg Dept Hepatobiliary &

    Endocrine Surg Nanning 530021;

    Peoples Hosp Guangxi Zhuang Autonomous Reg Dept Hepatobiliary &

    Endocrine Surg Nanning 530021;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

    breast cancer; microRNA-22; Sirtuin1; growth; metastasis;

    机译:乳腺癌;microRNA-22;SIRTUIN1;生长;转移;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号